Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.
Hoffman
Rosalind G
RG
Mount Sinai Medical Center, New York, New York 10029, USA.
Cohen
Mary Ann
MA
Alfonso
César A
CA
Weiss
Jeffrey J
JJ
Jones
Sian
S
Keller
Marla
M
Condemarín
Juan R
JR
Chiu
Nien-Mu
NM
Jacobson
Jeffrey M
JM
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000139:chemically induced / Q000175:diagnosis / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011605:Psychoses, Substance-Induced / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D000998:Antiviral Agents; D016898:Interferon-alpha; D001569:Benzodiazepines; D010890:Pirenzepine; D012254:Ribavirin; D000077152:Olanzapine